SPOTLIGHT: Merck sees gains with experimental HIV therapy

Merck announced that its experimental MK-0518 significantly reduced HIV virus levels in a mid-stage clinical trial. The drug blocks an enzyme that is needed to allow the virus to penetrate a cell and was used in 35 patients over 10 days. Report

Suggested Articles

One day after its Opdivo-paired prospect flopped, Five Prime is farming out some preclinical antibodies to keep its clinical-stage pipeline alive.

Gilead has a new head of research biology: Michael Quigley, Ph.D., an alum of MedImmune, Janssen and Dana Farber, who joins from Bristol-Myers Squibb.

The back-to-back pivotal successes tee Incyte up to talk to regulators about bringing the JAK inhibitor to market.